Articles

The entourage effect: where the idea came from and what supports it

A theory born in a Jerusalem laboratory in 1998, extended to the plant in 2011, and still mostly tested in cells and mice rather than people.

2026-09-24

The original finding was about the body, not the plant

The term entourage effect entered the literature in 1998, in a paper from Raphael Mechoulam's group at the Hebrew University of Jerusalem. The subject was not cannabis but the body's own system.

The researchers found that two fatty acid glycerol esters, inactive on their own, increased the cannabinoid activity of 2-arachidonoylglycerol — one of the endocannabinoids the body makes itself. Compounds that did nothing alone changed what an active compound did. That was the entourage.

Extended to the plant

The idea was carried over to cannabis most influentially by Dr Ethan Russo in 2011, in a review arguing that the plant's cannabinoids and terpenes act together in ways none of them does alone — and that this could explain why whole-plant preparations and isolated THC are reported to behave differently.

The review is a synthesis and a proposal, not an experiment. It is worth reading as the clearest statement of the hypothesis rather than as its proof.

The strongest single piece of evidence

If one finding carries the idea that terpenes matter pharmacologically, it is beta-caryophyllene. In 2008 a group led by Jürg Gertsch showed that this common plant terpene binds the CB2 receptor selectively and acts as a full agonist, with an affinity in the nanomolar range.

Two details make it striking. Beta-caryophyllene occurs widely in food — in pepper, cloves and much else — and is an approved food flavouring, which is why the paper is titled a dietary cannabinoid. And it is found well outside the cannabis genus, so the plant is not the only source of compounds that speak to these receptors.

The evidence that the effect runs through CB2 is direct: orally administered beta-caryophyllene produced anti-inflammatory and analgesic effects in normal mice but not in mice lacking the CB2 receptor.

What is solid and what is not

Solid: individual compounds beyond THC and CBD have real pharmacological targets, and beta-caryophyllene at CB2 is the clearest case.

Not solid: that the mixture in any given plant produces a predictable combined effect in a person. Most of the supporting work is preclinical — cell assays and animal models — and the concentrations of terpenes reaching the bloodstream from inhaled or swallowed cannabis are far lower than those used in laboratory experiments. The hypothesis is plausible, influential, and not settled.

It is also commercially convenient, which is a reason to read claims about it carefully rather than a reason to dismiss it.

Why the argument matters

If the entourage effect holds, studying isolated molecules will systematically misrepresent what the plant does, and regulation built around single-compound pharmaceuticals will miss the point. If it does not hold, whole-plant preparations are harder to standardise for no therapeutic gain.

The question is not academic. It shapes what gets researched, what gets licensed and what patients are offered.

← All articles